Sutro Biopharma Garners $26,000,000 Series D Funding

  • Feed Type
  • Date
    12/11/2013
  • Company Name
    Sutro Biopharma
  • Mailing Address
    310 Utah Ave. South San Francisco, CA 94080
  • Company Description
    Sutro Biopharma, Inc. is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease.
  • Website
    http://www.sutrobio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $26,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    The additional financing will fund the expansion of Sutro’s proprietary immuno-oncology product pipeline.
  • M&A Terms
  • Venture Investor
    Alta Partners
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    Celgene
  • Venture Investor
    Lilly Ventures
  • Venture Investor
    SV Life Sciences
  • Venture Investor
    Skyline Ventures